Patients who were unexpectedly hospitalized for dehydration, fever or other ailments while undergoing radiation treatment for head and neck cancers were at a higher risk for less favorable outcomes, a new study from Roswell Park Comprehensive Cancer Center reports.
New preclinical work by a team of researchers from Roswell Park Comprehensive Cancer Center’s Transplant and Cellular Therapy Program suggests that the risk of developing acute graft vs. host disease (GVHD) during allogeneic blood/marrow transplant (BMT) — a potentially curative treatment for selected patients with hematologic disorders — can be decreased using an existing class of drugs called beta adrenergic agonists.
Researchers at Roswell Park Comprehensive Cancer Center have been actively engaged in the effort to develop treatments or other control strategies that can help communities worldwide to address the impacts of the COVID-19 pandemic.
Clinical oncology pathways are an important tool, helping cancer care providers and their patients to zero in on the most appropriate care plan. But a treating professional’s decision to depart from the recommendations of these decision-support resources may be well-founded and in the patient’s best interests, a new Roswell Park study shows.
While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches. In a study to be presented at the American Society of Clinical Oncology (ASCO) 2020 virtual meeting, a Roswell Park Comprehensive Cancer Center team reports that in many cases, these newer treatment approaches may reduce the risk of therapy-related myelodysplastic syndrome or acute myeloid leukemia (tMDS/AML) compared to chemotherapy-based treatment strategies.
A possible new strategy for treating pancreatic cancer highlights the promise of collaboration between experts in both precision medicine and immunology. The findings from a team led by Agnieszka Witkiewicz, MD, and Erik Knudsen, PhD, at Roswell Park Comprehensive Cancer Center and published today in the journal Gut suggest a combination treatment approach that can make some breakthrough immunotherapy drugs effective for more patients with pancreatic cancer.
A two-drug immunotherapy combination first proposed by a Roswell Park team as an approach for treating cancer will soon be available to cancer patients with COVID-19 through a clinical trial at the Buffalo, N.Y., cancer center.
New research led by a pediatric oncology expert from Roswell Park Comprehensive Cancer Center underscores that diets high in antioxidant-rich foods can have particular benefits for young cancer patients.
Aggressive forms of prostate cancer don’t act the way they should, hanging on to genetic materials called introns that should be thrown away, researchers from Roswell Park reported today in Nature Communications.
Radiation is one of the oldest and most common therapies for cancer, and typically is delivered locally, or to specific targeted sites in the body. While it has long been thought that locally-delivered radiation therapy typically does not help to shrink tumors outside the field of irradiation, new preclinical research from a team at Roswell Park Comprehensive Cancer Center suggests a strategy for significantly increasing both the local and distant, or “abscopal,” effects of radiation. Results of the study, which was led by Elizabeth Repasky, PhD, have been newly published in Nature Communications.
Roswell Park will offer plasma from the donated blood of healthy individuals who have had COVID-19 but have now fully recovered to patients with severe or life-threatening COVID-19 through an expanded access program authorized by the U.S. FDA.
New research from Roswell Park Comprehensive Cancer Center, published in the Journal of the National Cancer Institute, shows that following those guidelines can improve clinical outcomes for patients with high-risk breast cancer, or breast cancer that is likely to recur or spread.
A team led by Pawel Kalinski, MD, PhD, of Roswell Park Comprehensive Cancer Center has earned a five-year, $14.54 million award from the National Cancer Institute (NCI) to expand a promising immunotherapy platform. Funded through the NCI’s Program Project Grant program, this prestigious five-year grant will fund five clinical trials, all focused on a strategy for making some of the most common immunotherapies work for more cancer patients.
A team of researchers from Roswell Park Comprehensive Cancer Center and the CDC report new evidence that inhalation of vitamin E acetate is strongly linked to e-cigarette, or vaping, product use-associated lung injury (EVALI).
The inventors of a cancer immunotherapy developed at Roswell Park Comprehensive Cancer Center have announced a major step forward with that therapy, SurVaxM — a multimillion-dollar licensing deal that will help enable large, randomized clinical trials in both the U.S. and China.
Roswell Park's Dr. Clare Twist led an effort to develop and validate a new treatment algorithm for infants and children with neuroblastoma. In a new study in the Journal of Clinical Oncology, the team reports that many patients can safely receive less extensive therapy.
In companion presentations at the American Society for Therapeutic Radiation Oncology Annual Meeting, doctors from Roswell Park Comprehensive Cancer Center report new evidence that low-dose aspirin and other anti-inflammatories may improve survival in patients with some head/neck and lung cancers.
A team from Roswell Park Comprehensive Cancer Center is moving a new three-part strategy for treating advanced cancers forward with support from a DoD grant that will fund a clinical trial in patients with brain-metastatic breast cancer.
Roswell Park researchers have received recent grant awards totaling more than $15.4 million. These competitive awards include the first National Institutes of Health funding to study a new electronic tobacco device and a state grant supporting Roswell Park's work with the national Cancer Moonshot.
Roswell Park researchers have uncovered a biomarker that may help explain why some patients respond better than others to sorafenib, a chemotherapy commonly prescribed for patients with advanced liver cancer.
Researchers from Roswell Park have developed a new bioinformatics-based approach for monitoring key changes in cancer cells — a data-driven method that might help to enhance and personalize cancer treatment.
A cancer therapy based on the work of Ben Seon, PhD, at Roswell Park Comprehensive Cancer Center has been approved by the U.S. Food and Drug Administration (FDA) for patients with an aggressive form of non-Hodgkin lymphoma.
Jens Hillengass, MD, Chief of Myeloma at Roswell Park Comprehensive Cancer Center, led an International Myeloma Working Group (IMWG) effort to compile new recommendations for imaging techniques that offer more sensitive and accurate diagnosis and monitoring for patients with multiple myeloma and other plasma-cell disorders.
With their phase II study in patients with aggressive brain cancer now completed, the developers of the cancer immunotherapy SurVaxM report that combination therapy with the vaccine was more effective than standard therapy for nearly all patients.
A clinical trial underway at Roswell Park Comprehensive Cancer Center will assess a brand-new immunotherapy approach — reprogramming a patient’s blood stem cells to generate a lasting supply of two types of immune cells — in patients with recurrent cancer of the ovaries, fallopian tubes or peritoneum.
In a new article in JNCI reporting the first known prognostic marker for triple-negative breast cancer, researchers provide evidence that a widely used breast cancer drug, tamoxifen, may be effective against this notoriously aggressive disease subtype.
A team from Roswell Park Comprehensive Cancer Center and the University at Buffalo reports that the protective benefit of oral contraceptives is most pronounced with the most aggressive and fatal subtypes of ovarian cancer.
Final results from the first U.S. clinical study of CIMAvax-EGF show that this Cuban immunotherapy is safe and showed promising efficacy as part of a treatment combination with nivolumab in patients with advanced non-small cell lung cancer.
Several Roswell Park Comprehensive Cancer Center experts were invited to highlight research and best practices during the TCT/Transplantation and Cellular Therapy Meetings now underway in Houston, Texas.
Roswell Park Comprehensive Cancer Center has been recognized as one of America’s Best Employers for Diversity 2019. The Buffalo cancer center was ranked 67th among 500 employers and 8th among the 30 employers within the health care sector to be named to the list, which is based on employee surveys.
The largest study to date to compare exposure to toxicants among users of electronic cigarettes, smokers and nonsmokers has been completed, suggesting possible benefits for smokers who switch completely to electronic cigarettes
New research out of Roswell Park Comprehensive Cancer Center shows that cancer patients who exercise regularly both before and after their diagnosis are significantly more likely to survive than those who are sedentary, adding to the growing body of evidence that physical activity is an important part of a cancer prevention and treatment strategy. The results were published in a recent issue of the journal Cancer Causes & Control.
Pain after surgery can be effectively managed with minimal or no opioids, according to research conducted at Roswell Park Comprehensive Cancer Center and published today in JAMA Network Open. A two-year study by a multidisciplinary team of surgeons and other cancer specialists shows that the amount of opioid medications prescribed after surgery can be drastically reduced without negatively affecting pain scores, postoperative complications or patient requests for additional
The latest results from an ongoing clinical study incorporating the immunotherapy SurVaxM as part of combination treatment for glioblastoma show that this investigational drug is safe, well-tolerated and extended survival even among the hardest-to-treat subgroups of patients. The findings were presented at the Society for Neuro-Oncology Annual Meeting in New Orleans.
In an effort to compile and summarize the latest knowledge about these immunotherapy combinations and their implications, a group of kidney cancer immunotherapy experts led by Saby George, MD, of Roswell Park Comprehensive Cancer Center have written a new research review article assessing current approaches to treating patients newly diagnosed with kidney cancer and also looking ahead to some of the most pressing questions still to be answered related to these emerging therapies. Published online Nov. 21 by the journal JAMA Oncology, the review article highlights the path to approval for the new standard of care for these patients — ipilimumab, also known as Yervoy, together with nivolumab, also known as Opdivo.
A new derivative of a compound found in the bark of a rare Chinese tree has powerful anticancer properties and a low toxicity profile, according to new research from a Roswell Park Comprehensive Cancer Center published in the Journal of Experimental & Clinical Cancer Research.
Governor Andrew M. Cuomo today announced Buffalo-based Roswell Park Comprehensive Cancer Center has formed the Innovative Immunotherapy Alliance S.A., the first-ever biotech venture between the U.S. and Cuba.
A new Roswell Park/Stony Brook Children's Hospital study reports striking findings: that young users of newer “pod” e-cigarette devices are absorbing nicotine at levels approaching nicotine exposure from traditional combustible cigarettes.
A Roswell Park-led research team has linked the development of castration-resistant prostate cancer and resistance to treatment to a lack of androgen receptor expression in prostate cancer cells, identifying a new therapeutic target. Their findings were published in the journal Nature Communications.
A research team from Roswell Park Comprehensive Cancer Center has discovered a way to use computed tomography (CT) imaging to assess kidney tumors that test positive for the biomarker CD117 and accurately determine — before surgery — whether the tumor is benign or malignant.
Research to be presented at the ASCO 2018 Annual Meeting suggests that a new treatment combination can extend survival for many patients with advanced colorectal cancer and that its efficacy compares favorably to single-agent approaches.
Roswell Park Comprehensive Cancer Center researchers have identified significant differences in the immune microenvironment of breast cancer tumors between African-American and white women, shedding light on the ways in which race can influence cancer development and outcomes. The findings, to be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, are based on based on a comprehensive review of data from The Cancer Genome Atlas.
Presenting new data at ASCO 2018, collaborators from Roswell Park Comprehensive Cancer Center, the Cleveland Clinic and MimiVax LLC report that the combination of SurVaxM plus standard therapy for patients with glioblastoma appears to be safe, effective and worthy of further evaluation.